Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
Launched by PFIZER · May 8, 2002
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Parkinson's disease of less than 7 years duration
- • Modified Hoehn and Yahr Scale Stages 1 through 3.
- • Age greater than or equal to 30 years old.
- • Men or women (women of childbearing potential must have a negative pregnancy test at screen) and both must use adequate contraceptive methods.
- • Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Exclusion Criteria:
- • Atypical Parkinson's disease syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases.
- • Levodopa received for 1-year accumulated interval in the last two years.
- • Dopamine agonist medications or catechol-o-methyl transferase inhibitors in the 30 days prior to baseline.
- • Unstable dose regimes of hypnotics, anxiolytics or antidepressants
- • Dementia
- • History of stereotaxic brain surgery, psychosis or active epilepsy within past year.
- • Participation in clinical trial within the previous 30 days.
- • Malignant melanoma or history of melanoma
- • Significant medical or pshychiatric condition.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Atlanta, Georgia, United States
Decatur, Georgia, United States
Mineola, New York, United States
New York, New York, United States
Sellersville, Pennsylvania, United States
San Antonio, Texas, United States
Springfield, Illinois, United States
Houston, Texas, United States
Richmond, Virginia, United States
Buenos Aires, , Argentina
Monterrey, Nuevo Leon, Mexico
Little Rock, Arkansas, United States
Fresno, California, United States
Irvine, California, United States
La Jolla, California, United States
Loma Linda, California, United States
Los Angeles, California, United States
Oceanside, California, United States
San Francisco, California, United States
San Luis Obiapo, California, United States
Walnut Creek, California, United States
Denver, Colorado, United States
Fairfield, Connecticut, United States
New Haven, Connecticut, United States
Wilmington, Delaware, United States
Boca Raton, Florida, United States
Clearwater, Florida, United States
Fort Lauderdale, Florida, United States
Jacksonville, Florida, United States
Maitland, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Orlando, Florida, United States
Palm Beach Gardens, Florida, United States
Plantation, Florida, United States
Tallahassee, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Decatur, Georgia, United States
Savannah, Georgia, United States
Chicago, Illinois, United States
Kansas City, Kansas, United States
Lake Charles, Louisiana, United States
Baltimore, Maryland, United States
Frederick, Maryland, United States
Boston, Massachusetts, United States
Grand Rapids, Michigan, United States
Traverse City, Michigan, United States
Golden Valley, Minnesota, United States
Minneapolis, Minnesota, United States
St. Cloud, Minnesota, United States
Springfield, Missouri, United States
Omaha, Nebraska, United States
Lebanon, New Hampshire, United States
Morristown, New Jersey, United States
New Brunswick, New Jersey, United States
Manhasset, New York, United States
Mineola, New York, United States
Mount Vernon, New York, United States
New York, New York, United States
Syracuse, New York, United States
Asheville, North Carolina, United States
Raleigh, North Carolina, United States
Oklahoma City, Oklahoma, United States
Norristown, Pennsylvania, United States
Sellersville, Pennsylvania, United States
Upland, Pennsylvania, United States
Knoxville, Tennessee, United States
Memphis, Tennessee, United States
Austin, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Burlington, Vermont, United States
Richmond, Virginia, United States
Bellevue, Washington, United States
Wenatchee, Washington, United States
Milwaukee, Wisconsin, United States
Buenos Aires, Barcelona, Argentina
Mar Del Plata, Buenos Aires, Argentina
Carolina, , Puerto Rico
Hot Springs, Arkansas, United States
Carmichael, California, United States
St. Petersburg, Florida, United States
Conyers, Georgia, United States
Glenbrook, Illinois, United States
Shreveport, Louisiana, United States
Columbia, Maryland, United States
Rockville, Maryland, United States
Ann Arbor, Michigan, United States
East Lansing, Michigan, United States
Southfield, Michigan, United States
Henderson, Nevada, United States
Ridgewood, New Jersey, United States
Nashville, Tennessee, United States
Spokane, Washington, United States
Mexico City, Mexico D.F., Mexico
Monterrey, Nuevo Leon, Mexico
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials